Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-25T18:14:57.718Z Has data issue: false hasContentIssue false
  • English
  • Français

The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis

Published online by Cambridge University Press:  15 April 2020

G. Faber ,
H.G.O.M. Smid ,
A.R. Van Gool ,
D. Wiersma  and
R.J. Van Den Bosch
G. Faber*
Affiliation:
Yulius, Mental Health Institute, Hellingen 21, 3311GZ Dordrecht, The Netherlands
H.G.O.M. Smid
Affiliation:
Department of psychiatry, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700RB Groningen, The Netherlands
A.R. Van Gool
Affiliation:
Yulius, Mental Health Institute, Hellingen 21, 3311GZ Dordrecht, The Netherlands
D. Wiersma
Affiliation:
Department of psychiatry, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700RB Groningen, The Netherlands
R.J. Van Den Bosch
Affiliation:
Department of psychiatry, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700RB Groningen, The Netherlands
*
*Corresponding author. Tel.: +31 653395358; fax: +31 102880785. E-mail address: g.faber@yulius.nl (G. Faber).
Get access

Abstract

Objective

To assess the effects of second generation antipsychotics on neurocognitive function in patients with stable remission of first episode psychosis.

Methods

Fifty-three patients with first onset psychosis in the schizophrenia spectrum entered a randomised controlled trial of guided discontinuation (GD) versus maintenance treatment (MT) with second generation antipsychotics. A comprehensive neurocognitive test battery was administered at the time of remission and shortly after dose reduction or discontinuation (GD-group) or at the same time in the MT-group.

Results

With the exception of negative symptoms, PANSS scores decreased over time and neurocognition improved significantly on most tests in both groups. The GD-group, however, improved significantly more than the MT-group on three neurocognitive measures in the domain of speed of processing.

Conclusion

These data suggest that, in first episode patients, dose reduction or discontinuation of second generation antipsychotics after stable remission is achieved, might improve neurocognitive function more than continuing second generation antipsychotics, suggesting a negative role for second generation antipsychotics, specifically in the domain of speed of processing.

Keywords

SchizophreniaAntipsychoticsNeurocognitive functionGuided discontinuation
Type
Original articles
Information
European Psychiatry , Volume 27 , Issue 4 , May 2012 , pp. 275 - 280
Copyright
Copyright © Elsevier Masson SAS 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2nd ed. Am J Psychiatry 2004;161(Suppl. 2).Google Scholar
Barker, M.J., Greenwood, K.M., Jackson, M., Crow, S.F.Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol. 2004; 19: 437–454.CrossRefGoogle ScholarPubMed
de Bruijn, E.R.A., Sabbe, B.G.C., Hulstijn, W., Ruigt, G.S.F., Verkes, R.J.Effects of antipsychotic and antidepressant drugs on action monitoring in healthy volunteers. Brain Res. 2006; 1105: 122–129.CrossRefGoogle ScholarPubMed
Carpenter, W.T., Gold, J.M.Another view of therapy for cognition in schizophrenia. Biol Psychiatry. 2003; 52: 969–971.Google Scholar
Conway Greig, T., Nicholls, S.S., Wexler, B.E., Bell, M.D.Test-retest stability of neuropsychological testing and individual differences in variability in schizophrenia outpatients. Psychiatry Res. 2004; 129: 241–247.CrossRefGoogle ScholarPubMed
Davidson, M., Galderisi, S., Weise, M., Werbeloff, N., Fleischhacker, W.W., Keefe, R.S.et al.Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009; 166: 675–682.CrossRefGoogle ScholarPubMed
Green, M.F.What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry. 1996; 153: 321–330.Google Scholar
Green, M.F., Kern, R.S., Braff, D.L., Mintz, J.Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?. Schizophr Bull. 2000; 26: 119–136.CrossRefGoogle ScholarPubMed
Green, M.F., Kern, R.S., Heaton, R.K.Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004; 72: 41–51.CrossRefGoogle ScholarPubMed
Goldberg, T.E., Goldman, R.S., Burdick, K.E., Malhotra, A.K., Lencz, T., Patel, R.C.et al.Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia. Is it a practice effect?. Arch Gen Psychiatry. 2007; 64: 1115–1122.CrossRefGoogle ScholarPubMed
Harvey, P.D., Keefe, R.S.E.Studies in cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001; 158: 176–184.CrossRefGoogle ScholarPubMed
Harvey, P.D., Palmer, B.W., Heaton, R.K., Mohamed, S., Kennedy, J., Brickman, A.Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study. Am J Psychiatry. 2005; 162: 110–117.CrossRefGoogle ScholarPubMed
Harvey, P.D., Rabinowitz, J., Eerdekens, M., Davidson, M.Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005; 162: 1888–1895.CrossRefGoogle Scholar
Heinrichs, R.W., Zakzanis, K.K.Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998; 12: 426–445.CrossRefGoogle Scholar
Kay, S.R., Fiszbein, A., Opler, L.A.The Positive and Negative Syndrome Scale for schizophrenia. Schizophr Bull. 1987; 13: 261–276.CrossRefGoogle Scholar
Keefe, R.S.E., Seidman, L.J., Christensen, B.K., Hamer, R.M., Sharma, T., Sitskoorn, M.M.et al.Comparative effect of atypical and conventional drugs on neurocognition in first-episode psychosis: a randomised, double-blind trial of olanzapine versus low dose of haloperidol. Am J Psychiatry. 2004; 161: 985–995.CrossRefGoogle Scholar
Keefe, R.S.E., Seidman, L.J., Christensen, B.K., Hamer, R.M., Sharma, T., Sitskoorn, M.M.et al.Long-term neurocognitive effects of olanzapine or low dose of haloperidol in first-episode psychosis. Biol Psychiatry. 2006; 59: 97–105.CrossRefGoogle ScholarPubMed
Keefe, R.S.E., Bilder, R.M., Davis, S.M., Harvey, P.D., Palmer, B.W., Gold, J.M.et al.Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007; 64: 633–647.CrossRefGoogle ScholarPubMed
Lezak, M.Neuropsychological assessment. 3rd ed.New York, NY: Oxford University Press; 1995.Google Scholar
Minzenberg, M.J., Poole, J.H., Benton, C., Vinogradov, S.Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004; 161: 116–124.CrossRefGoogle Scholar
Nuechterlein, K.H., Barch, D.M., Gold, J.M., Goldberg, T.E., Green, M.F., Heaton, R.K.Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004; 72: 29–39.CrossRefGoogle Scholar
Nuechterlein, K.H., Green, M.F., Kern, R.S., Baade, L.E., Barch, D.M., Cohen, J.D.et al.The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008; 165: 203–213.CrossRefGoogle ScholarPubMed
O’Carroll, R.E., Smith, K., Couston, M., Cossar, J.A., Hayes, P.C.A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation. Qual Life Res. 2009; 9: 121–124.CrossRefGoogle Scholar
Potkin, S.G., Fleming, K., Jin, Y., Gulasekaram, B.Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychopharmacol. 2001; 21: 479–483.CrossRefGoogle ScholarPubMed
Rodriguez-Sanchez, J.M., Crespo-Facorro, B., Gonzalez-Blanch, C., Perez-Iglesias, R., Vazquez-Barquero, J.L.Cognitive dysfunction in first-episode psychosis: the processing speed hypothesis. Br J Psychiatry. 191 suppl. 51: 2007 107–110.CrossRefGoogle Scholar
SPSS 15.0 for Windows. SPSS Inc., Chicago Ill; 2006.Google Scholar
Wechsler, D.WAIS-III: Wechsler Adult Intelligence Scale. Administration and scoring manual. 3rd ed. 1997 Psychological Corporation/Harcourt Brace San Antonio, Texas.Google Scholar
Weickert, T.W., Goldberg, T.E., Marenco, S., Bigelow, L.B., Egan, M.F., Weinberger, D.R.Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology. 2003; 28: 1491–1500.CrossRefGoogle Scholar
Woodward, N.D., Purdon, S.E., Meltzer, H.Y., Zald, D.H.A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005; 8: 457–472.CrossRefGoogle Scholar
Woodward, N.D., Purdon, S.E., Meltzer, H.Y., Zald, D.H.A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res. 2007; 89: 211–224.CrossRefGoogle ScholarPubMed
World Health Organisation. Schedules for Clinical Assessment in Neuropsychiatry; 1992. WHO. Dutch version; 1999.Google Scholar
Wunderink, L., Nienhuis, F.J., Sytema, S., Slooff, C.J., Knegtering, H., Wiersma, D.Guided discontinuation versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007; 68: 654–661.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.